Faeth Therapeutics
FTH
40 hedge funds and large institutions have $45.8M invested in Faeth Therapeutics in 2021 Q1 according to their latest regulatory filings, with 40 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
10.31% more ownership
Funds ownership: 0% → 10.31% (+10%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$11.6M |
| 2 |
Deerfield Management
New York
|
+$6.28M |
| 3 |
BlackRock
New York
|
+$5.57M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.43M |
| 5 |
Alpha Wave Global
New York
|
+$3.58M |
Top Sellers
FTH Hedge Fund Activity: Q1 2021 in Review
40 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Faeth Therapeutics (FTH) for Q1 2021, worth a combined $45.8M.
Buyers outnumbered sellers: 40 funds opened new FTH positions and 0 closed out — a net gain of 40 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $11.6M.
- 40 institutional investors held Faeth Therapeutics (FTH) as of Q1 2021, up from 0 in Q4 2020.
- Funds reported $45.8M of Faeth Therapeutics stock for Q1 2021.
- 40 funds opened new Faeth Therapeutics positions in Q1 2021 and 0 closed out, a net change of +40 holders.
- The largest Faeth Therapeutics buyer in Q1 2021 was Citadel Advisors, an estimated $11.6M added.
Based on aggregated 13F filings for Q1 2021.